Ocular comorbidities are common in multiple myeloma: results of a large cross-sectional survey
The Oncologist · 14.11.2026
DOI: 10.1093/oncolo/oyag458 ↗Kurz gefasst
Querschnittstudie in der Zeitschrift The Oncologist, online erschienen am 14.11.2026. Verfasst von Rahul Banerjee und 9 weiteren Autor:innen. Beteiligte Einrichtung: Fred Hutchinson Cancer Center, Seattle, WA, USA. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Both advancing age and multiple myeloma (MM) therapies such as belantamab mafodotin or dexamethasone can be risk factors for ocular complications. We conducted an international online survey of 508 patients with MM; 3% and 2% reported previous craniofacial radiation therapy or belantamab mafodotin, respectively. Common ocular comorbidities included cataracts (59%), dry eyes requiring eyedrops (37%), and blepharitis or styes (24%). Higher typical dexamethasone doses (≥20 milligrams weekly) were associated with cataracts after adjusting for advancing age and time since diagnosis. Compared to lower-dose dexamethasone (0-19 milligrams weekly), high-dose dexamethasone shifted the incidence curve of predicted cataracts approximately 5.4 years earlier. Although 82% of patients reported periodic eye exams (in line with ophthalmologic recommendations for older adults), only 31% had ever received such guidance from their MM teams. In conclusion, ocular issues are common in MM. Corticosteroid-sparing regimens may warrant attention across the age spectrum to reduce the risk of cataracts.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Fred Hutchinson Cancer Center, Seattle, WA, USA.
- University of Washington, Seattle, WA, USA.
- HealthTree Foundation, Lehi, UT, USA.
- Mount Sinai School of Medicine, New York, NY, USA.
- BC Cancer Agency, Vancouver, BC, Canada.
ORCID-Profile: Rahul Banerjee
Zitieren
APA
Banerjee, R., Hydren, J., Hurtado Martínez, J. A., Barnes, M., Flores Pérez, P. A., Ahlstrom, J. M., Cicero, K. I., Kaur, G., Taravati, P., & Cowan, A. J. (2026). Ocular comorbidities are common in multiple myeloma: results of a large cross-sectional survey. The Oncologist. https://doi.org/10.1093/oncolo/oyag458
Vancouver
Banerjee R, Hydren J, Hurtado Martínez JA, Barnes M, Flores Pérez PA, Ahlstrom JM, et al. Ocular comorbidities are common in multiple myeloma: results of a large cross-sectional survey. The Oncologist. 2026. doi:10.1093/oncolo/oyag458
BibTeX
@article{Banerjee2026,
author = {Banerjee, Rahul and Hydren, Jay and Hurtado Martínez, Jorge Arturo and Barnes, Mason and Flores Pérez, Patricia Alejandra and Ahlstrom, Jennifer M and Cicero, Kara I and Kaur, Gurbakhash and Taravati, Parisa and Cowan, Andrew J},
title = {Ocular comorbidities are common in multiple myeloma: results of a large cross-sectional survey},
journal = {The Oncologist},
year = {2026},
doi = {10.1093/oncolo/oyag458}
}
EUVIMED